These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23494656)

  • 1. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study.
    Borgwardt L; Dali CI; Fogh J; Månsson JE; Olsen KJ; Beck HC; Nielsen KG; Nielsen LH; Olsen SO; Riise Stensland HM; Nilssen O; Wibrand F; Thuesen AM; Pearl T; Haugsted U; Saftig P; Blanz J; Jones SA; Tylki-Szymanska A; Guffon-Fouiloux N; Beck M; Lund AM
    J Inherit Metab Dis; 2013 Nov; 36(6):1015-24. PubMed ID: 23494656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis.
    Harmatz P; Cattaneo F; Ardigò D; Geraci S; Hennermann JB; Guffon N; Lund A; Hendriksz CJ; Borgwardt L
    Mol Genet Metab; 2018 Jun; 124(2):152-160. PubMed ID: 29716835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy in alpha-mannosidosis guinea-pigs.
    Crawley AC; King B; Berg T; Meikle PJ; Hopwood JJ
    Mol Genet Metab; 2006; 89(1-2):48-57. PubMed ID: 16807033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice.
    Stroobants S; Damme M; Van der Jeugd A; Vermaercke B; Andersson C; Fogh J; Saftig P; Blanz J; D'Hooge R
    Neurobiol Dis; 2017 Oct; 106():255-268. PubMed ID: 28720484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.
    Lund AM; Borgwardt L; Cattaneo F; Ardigò D; Geraci S; Gil-Campos M; De Meirleir L; Laroche C; Dolhem P; Cole D; Tylki-Szymanska A; Lopez-Rodriguez M; Guillén-Navarro E; Dali CI; Héron B; Fogh J; Muschol N; Phillips D; Van den Hout JMH; Jones SA; Amraoui Y; Harmatz P; Guffon N
    J Inherit Metab Dis; 2018 Nov; 41(6):1225-1233. PubMed ID: 29725868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.
    Blanz J; Stroobants S; Lüllmann-Rauch R; Morelle W; Lüdemann M; D'Hooge R; Reuterwall H; Michalski JC; Fogh J; Andersson C; Saftig P
    Hum Mol Genet; 2008 Nov; 17(22):3437-45. PubMed ID: 18713755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial.
    Borgwardt L; Guffon N; Amraoui Y; Dali CI; De Meirleir L; Gil-Campos M; Heron B; Geraci S; Ardigò D; Cattaneo F; Fogh J; Van den Hout JMH; Beck M; Jones SA; Tylki-Szymanska A; Haugsted U; Lund AM
    J Inherit Metab Dis; 2018 Nov; 41(6):1215-1223. PubMed ID: 29846843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study.
    Roces DP; Lüllmann-Rauch R; Peng J; Balducci C; Andersson C; Tollersrud O; Fogh J; Orlacchio A; Beccari T; Saftig P; von Figura K
    Hum Mol Genet; 2004 Sep; 13(18):1979-88. PubMed ID: 15269179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis.
    Damme M; Stroobants S; Walkley SU; Lüllmann-Rauch R; D'Hooge R; Fogh J; Saftig P; Lübke T; Blanz J
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):83-94. PubMed ID: 21157375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study.
    Guffon N; Konstantopoulou V; Hennermann JB; Muschol N; Bruno I; Tummolo A; Ceravolo F; Zardi G; Ballabeni A; Lund A
    J Inherit Metab Dis; 2023 Jul; 46(4):705-719. PubMed ID: 36849760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.
    Damme M; Stroobants S; Lüdemann M; Rothaug M; Lüllmann-Rauch R; Beck HC; Ericsson A; Andersson C; Fogh J; D'Hooge R; Saftig P; Blanz J
    Ann Clin Transl Neurol; 2015 Nov; 2(11):987-1001. PubMed ID: 26817023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal alpha-mannosidase and alpha-mannosidosis.
    Paciotti S; Codini M; Tasegian A; Ceccarini MR; Cataldi S; Arcuri C; Fioretti B; Albi E; Beccari T
    Front Biosci (Landmark Ed); 2017 Jan; 22(1):157-167. PubMed ID: 27814608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation.
    Borgwardt L; Stensland HM; Olsen KJ; Wibrand F; Klenow HB; Beck M; Amraoui Y; Arash L; Fogh J; Nilssen Ø; Dali CI; Lund AM
    Orphanet J Rare Dis; 2015 Jun; 10():70. PubMed ID: 26048034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis.
    Borgwardt L; Thuesen AM; Olsen KJ; Fogh J; Dali CI; Lund AM
    J Inherit Metab Dis; 2015 Nov; 38(6):1119-27. PubMed ID: 26016802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis.
    Zielonka M; Garbade SF; Kölker S; Hoffmann GF; Ries M
    J Inherit Metab Dis; 2019 Sep; 42(5):975-983. PubMed ID: 31222755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis.
    Hennermann JB; Guffon N; Cattaneo F; Ceravolo F; Borgwardt L; Lund AM; Gil-Campos M; Tylki-Szymanska A; Muschol NM
    Orphanet J Rare Dis; 2020 Sep; 15(1):271. PubMed ID: 32993743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired lysosomal trimming of N-linked oligosaccharides leads to hyperglycosylation of native lysosomal proteins in mice with alpha-mannosidosis.
    Damme M; Morelle W; Schmidt B; Andersson C; Fogh J; Michalski JC; Lübke T
    Mol Cell Biol; 2010 Jan; 30(1):273-83. PubMed ID: 19884343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can velmanase alfa be the next widespread potential therapy for alpha-mannosidosis?
    Abdul Ghani S; Burney S; Ul Hussain H; Abdul Wahid M; Mumtaz H
    Int J Surg; 2023 Sep; 109(9):2882-2885. PubMed ID: 37352513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-Mannosidosis: Therapeutic Strategies.
    Ceccarini MR; Codini M; Conte C; Patria F; Cataldi S; Bertelli M; Albi E; Beccari T
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical evaluation of patients with alpha-mannosidosis - A multicenter study.
    Köse E; Kasapkara ÇS; İnci A; Yıldız Y; Sürücü Kara İ; Kahraman AB; Tümer L; Dursun A; Eminoğlu FT
    Eur J Med Genet; 2024 Apr; 68():104927. PubMed ID: 38382588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.